What is the 13F Pro Quality Score for IGC?

13F Pro ranks IGC Pharma, Inc. (IGC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IGC's current score at https://13fpro.ai/research/IGC (free sign-up required for the full ranking).

Where does 13F Pro source IGC data?

All IGC Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. IGC Pharma, Inc. files with the SEC under CIK 1326205. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IGC in?

IGC Pharma, Inc. (IGC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IGC research updated on 13F Pro?

IGC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IGC Pharma, Inc.(IGC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1326205 IGC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $8.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IGC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IGC Pharma, Inc. (IGC), a Healthcare sector company. IGC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $8.0m in revenue. Based on the latest XBRL financial filings (Q4 2026), IGC Pharma, Inc. reports quarterly revenue of $317.0K, net income of $-2.4M, free cash flow of $-1.2M. Top institutional holders of IGC by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, BlackRock,, based on the most recent SEC filings. IGC trades on the NYSE exchange and files with the SEC under CIK 1326205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IGC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IGC Pharma, Inc. directly from SEC EDGAR.

Revenue

Q4 2026

$317.0K

Net Income

Q4 2026

$-2.4M

Free Cash Flow

Q4 2026

$-1.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-5.5% YoY

$1.3MFY 2025

FY21 $898.0KFY22 $397.0KFY24 $1.3MFY25 $1.3M

Net Income

+45.2% YoY

$-7.1MFY 2025

FY21 $-8.8MFY22 $-15.0MFY24 $-13.0MFY25 $-7.1M

Operating Income

+24.0% YoY

$-7.4MFY 2025

FY21 $-8.7MFY22 $-15.4MFY24 $-9.8MFY25 $-7.4M

EPS (Diluted)

+59.1% YoY

$-0.09FY 2025

FY21 —FY22 —FY24 $-0.22FY25 $-0.09

Total Assets

-11.7% YoY

$8.7MFY 2025

FY21 $35.9MFY22 $26.8MFY24 $9.9MFY25 $8.7M

Total Debt

-2.1% YoY

$137.0KFY 2025

FY21 $580.0KFY22 $147.0KFY24 $140.0KFY25 $137.0K

Op. Cash Flow

+7.8% YoY

$-4.8MFY 2025

FY21 $-10.8MFY22 $-7.5MFY24 $-5.2MFY25 $-4.8M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$1.3M -5.5%	$1.3M +238.8%	$397.0K -55.8%	$898.0K -77.9%	$4.1M -20.4%	$5.1M
Net Income	$-7.1M +45.2%	$-13.0M +13.4%	$-15.0M -70.4%	$-8.8M -20.5%	$-7.3M -78.5%	$-4.1M
Operating Income	$-7.4M +24.0%	$-9.8M +36.5%	$-15.4M -76.8%	$-8.7M -27.1%	$-6.9M -47.8%	$-4.6M
EPS (Diluted)	$-0.09 +59.1%	$-0.22	—	—	—	—
Total Assets	$8.7M -11.7%	$9.9M -63.1%	$26.8M -25.2%	$35.9M +23.7%	$29.0M -15.9%	$34.5M
Total Debt	$137.0K -2.1%	$140.0K -4.8%	$147.0K -74.7%	$580.0K +1060.0%	$50.0K +0.0%	$50.0K
Operating Cash Flow	$-4.8M +7.8%	$-5.2M +30.3%	$-7.5M +30.9%	$-10.8M -24.5%	$-8.7M -160.6%	$-3.3M

AI Insight: IGC Financial Trends

IGC posted first profitable quarter in Q4 2025 ($2M net income) but revenue remains absent and operating losses persist.

• Net income swung to +$2M in Q4 2025 from −$1M to −$2M range in prior quarters, marking first profitable result in dataset.

• Revenue remains $0M across all periods; no commercial traction evident despite profitability milestone in Q4 2025.

• Operating income stayed negative at −$2M in Q4 2025 and Q1 2026, inconsistent with net income swing—suggests one-time gains or non-operating items.

⚠ Q4 2025 net income profitability not explained by operating improvements; operating CF remains negative. Sustainability unclear.

⚠ Revenue generation has not started; company continues burning cash with negative operating CF each quarter.

AI Insight: IGC Ratio Trends

IGC Pharma oscillates between profitability and deep losses with no sustained earnings power; latest quarter reverted to -157% ROE after brief Q4 2025 spike.

• ROE swung dramatically from -116.9% in Q4 2024 to +95.8% in Q4 2025, then collapsed to -157.0% in Q1 2026.

• ROA shows similar volatility: -80.6% in Q4 2024, improved to +73.2% in Q4 2025, then deteriorated to unspecified in Q1 2026 TTM.

• ROIC turned negative -90.6% in Q4 2025; capital generation remains severely impaired.

⚠ No operating or net profit margins reported across any period—inability to measure core profitability suggests structural earnings instability.

⚠ Leverage stable at 0.02 D/E, but immaterial given negative returns; balance sheet strength is irrelevant without earnings.

Get alerted when IGC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IGC Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IGC

GEODE CAPITAL MANAGEMENT, LLC
$274.4K1,043,384 sh
VANGUARD CAPITAL MANAGEMENT LLC
$188.9K718,436 sh
BlackRock, Inc.
$185.1K703,798 sh
RENAISSANCE TECHNOLOGIES LLC
$127.3K483,975 sh
VANGUARD FIDUCIARY TRUST CO
$109.4K415,888 sh
STATE STREET CORP
$52.8K200,799 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$32.2K122,595 sh
NORTHERN TRUST CORP
$29.8K113,407 sh
LAWOOD & CO
$19.7K75,000 sh
GOLDMAN SACHS GROUP INC
$17.2K65,541 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$274.4K	1,043,384
VANGUARD CAPITAL MANAGEMENT LLC	$188.9K	718,436
BlackRock, Inc.	$185.1K	703,798
RENAISSANCE TECHNOLOGIES LLC	$127.3K	483,975
VANGUARD FIDUCIARY TRUST CO	$109.4K	415,888
STATE STREET CORP	$52.8K	200,799
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$32.2K	122,595
NORTHERN TRUST CORP	$29.8K	113,407
LAWOOD & CO	$19.7K	75,000
GOLDMAN SACHS GROUP INC	$17.2K	65,541

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IGC on your watchlist

Track score changes the day IGC Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IGC a good stock to buy?

13F Pro's AI-powered analysis of IGC Pharma, Inc. (IGC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IGC are available on the IGC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IGC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IGC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IGC Pharma, Inc.'s investment landscape.